April 3, 2012

Eisai Diagnostics Subsidiary EIDIA Enters Into Sales Agreements with Medical Equipment Manufacturers for PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography

Tokyo, Apr 3, 2012 - (JCN Newswire) - Eisai Co., Ltd. and its diagnostics subsidiary EIDIA Co., Ltd. announced today that EIDIA entered into two separate agreements with medical equipment manufacturers Toshiba Medical Systems Corporation and GE Healthcare Japan Corporation on April 2 for Japan sales of PROTOCO2L, a carbon dioxide insufflation system for CT (computed tomographic) colonography, and carbon dioxide insufflation tube PROTOCO2L Catheter Set (collectively referred to as "the Product"), both of which are currently marketed by EIDIA.

The Product is used in CT colonography, a minimally invasive colorectal examination performed to detect lesions such as colorectal cancer through the use of CT imaging without requiring the insertion of a colonoscope into the colon. It uses medical carbon dioxide that is readily absorbed by the bowel, which allows for consistent distension of the large intestine and minimization of the discomfort incurred by patients during the procedure.

Carbon dioxide insufflation systems are widely utilized in both the United States and Europe in CT colonography as a useful screening tool for detecting and diagnosing colorectal cancer in its early stages. EIDIA launched the Product as the first system of its kind in Japan on August 22, 2011 to address the significant needs that existed in the medical setting.

The conclusion of the agreements will see the new addition of Toshiba Medical Systems and GE Healthcare Japan, both of which are major sellers of CT equipment in Japan, as powerful sales channels, and is expected to further contribute to the widespread use of CT colonography in colorectal exams and the early detection of colorectal cancer in Japan.

With a view to further fulfilling its corporate mission of human health care (hhc), the Eisai Group established a new Eisai Japan organizational structure in June 2010 to formulate and implement comprehensive strategies across its four Japan business segments comprising prescription pharmaceuticals, consumer healthcare products, diagnostics, and generics. By providing a wide range of information and products related to all aspects of integrative oncology, one of the Group's defined areas of therapeutic focus, Eisai and EIDIA seek to make further contributions to increasing the benefits provided to patients.

*The approval of the Product was announced in a news release entitled "PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography Receives Approval in Japan" on August 10, 2011.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html

Source: Eisai


Public Relations Department
Eisai Co. Ltd

Copyright 2011 JCN Newswire. All rights reserved. www.japancorp.net